Towards Healthcare
Cell and Gene Therapy Market Leads 24% Solid CAGR by 2034

Cell and Gene Therapy Market Size, Trends and Competitive Dynamics

Forecasts suggest that the cell and gene therapy market will expand USD 187.44 billion by 2034, with a CAGR of 24% during the forecasted period. Gene therapy is rapidly evolving, driven by CRISPR and CAR-T advancements. Once focused on rare diseases and cancer, it now targets neurological, cardiovascular, and autoimmune conditions. With fast-tracked approvals, major investments, and growing clinical trials, the future of gene therapy looks highly promising.

Content

Introduction

  • Research Objective
  • Scope of the Study
  • Definition and Taxonomy

Research Methodology

  • Research Approach
  • Data Sources
  • Assumptions

Executive Summary

  • Synopsis
  • Analyst Recommendations

Market Overview 

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Value Chain Analysis
    • Raw Material Sourcing
    • Manufacturing Process
    • Logistics & Transportation
    • Buyer Preferences
  • Trends
    • Market Trends
    • Technological Trends
  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers
    • Bargaining Power of Buyers
    • Threat of Substitute
    • Threat of New Entrants
    • Degree of Competition
  • PESTLE Analysis for 5 Leading Countries
    • Regulatory Framework for Leading Countries/Regions
    • Supply Demand Analysis
    • Production & Consumption Statistics
    • Export Import Statistics
    • Price Trend Analysis

Global Cell and Gene Therapy Market Assessment

  • Overview
  • Global Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Therapy Type (2021 – 2033)
    • Cell Therapy
      • Stem Cells
      • T Cells
      • Dendritic Cells
      • NK Cells
      • Tumor Cells
    • Gene Therapy
  • Global Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Therapeutic Class (2021 – 2033)
    • Cardiovascular Disease
    • Cancer
    • Genetic Disorder
    • Rare Diseases
    • Oncology
    • Hematology
    • Ophthalmology
    • Infectious Disease
    • Neurological Disorders
  • Global Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Delivery Method (2021 – 2033)
    • In Vivo
    • Ex vivo
  • Global Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by End-Users (2021 – 2033)
    • Hospitals
    • Cancer Care Centers
    • Wound Care Centers
    • Others
  • Global Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Region (2021 – 2033)
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • MEA

North America Cell and Gene Therapy Market Assessment

  • Overview
  • North America Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Therapy Type (2021 – 2033)
    • Cell Therapy
      • Stem Cells
      • T Cells
      • Dendritic Cells
      • NK Cells
      • Tumor Cells
    • Gene Therapy
  • North America Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Therapeutic Class (2021 – 2033)
    • Cardiovascular Disease
    • Cancer
    • Genetic Disorder
    • Rare Diseases
    • Oncology
    • Hematology
    • Ophthalmology
    • Infectious Disease
    • Neurological Disorders
  • North America Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Delivery Method (2021 – 2033)
    • In Vivo
    • Ex vivo
  • North America Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by End-Users (2021 – 2033)
    • Hospitals
    • Cancer Care Centers
    • Wound Care Centers
    • Others

Europe Cell and Gene Therapy Market Assessment

  • Overview
  • Europe Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Therapy Type (2021 – 2033)
    • Cell Therapy
      • Stem Cells
      • T Cells
      • Dendritic Cells
      • NK Cells
      • Tumor Cells
    • Gene Therapy
  • Europe Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Therapeutic Class (2021 – 2033)
    • Cardiovascular Disease
    • Cancer
    • Genetic Disorder
    • Rare Diseases
    • Oncology
    • Hematology
    • Ophthalmology
    • Infectious Disease
    • Neurological Disorders
  • Europe Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Delivery Method (2021 – 2033)
    • In Vivo
    • Ex vivo
  • Europe Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by End-Users (2021 – 2033)
    • Hospitals
    • Cancer Care Centers
    • Wound Care Centers
    • Others

Asia Pacific Cell and Gene Therapy Market Assessment

  • Overview
  • Asia Pacific Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Therapy Type (2021 – 2033)
    • Cell Therapy
      • Stem Cells
      • T Cells
      • Dendritic Cells
      • NK Cells
      • Tumor Cells
    • Gene Therapy
  • Asia Pacific Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Therapeutic Class (2021 – 2033)
    • Cardiovascular Disease
    • Cancer
    • Genetic Disorder
    • Rare Diseases
    • Oncology
    • Hematology
    • Ophthalmology
    • Infectious Disease
    • Neurological Disorders
  • Asia Pacific Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Delivery Method (2021 – 2033)
    • In Vivo
    • Ex vivo
  • Asia Pacific Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by End-Users (2021 – 2033)
    • Hospitals
    • Cancer Care Centers
    • Wound Care Centers
    • Others

Latin America Cell and Gene Therapy Market Assessment

  • Overview
  • Latin America Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Therapy Type (2021 – 2033)
    • Cell Therapy
      • Stem Cells
      • T Cells
      • Dendritic Cells
      • NK Cells
      • Tumor Cells
    • Gene Therapy
  • Latin America  Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Therapeutic Class (2021 – 2033)
    • Cardiovascular Disease
    • Cancer
    • Genetic Disorder
    • Rare Diseases
    • Oncology
    • Hematology
    • Ophthalmology
    • Infectious Disease
    • Neurological Disorders
  • Latin America Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Delivery Method (2021 – 2033)
    • In Vivo
    • Ex vivo
  • Latin America Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by End-Users (2021 – 2033)
    • Hospitals
    • Cancer Care Centers
    • Wound Care Centers
    • Others

MEA Cell and Gene Therapy Market Assessment

  • Overview
  • MEA Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Therapy Type (2021 – 2033)
    • Cell Therapy
      • Stem Cells
      • T Cells
      • Dendritic Cells
      • NK Cells
      • Tumor Cells
    • Gene Therapy
  • MEA Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Therapeutic Class (2021 – 2033)
    • Cardiovascular Disease
    • Cancer
    • Genetic Disorder
    • Rare Diseases
    • Oncology
    • Hematology
    • Ophthalmology
    • Infectious Disease
    • Neurological Disorders
  • MEA Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by Delivery Method (2021 – 2033)
    • In Vivo
    • Ex vivo
  • MEA Cell and Gene Therapy Market Size Value (US$) and Volume (Billion Tons), by End-Users (2021 – 2033)
    • Hospitals
    • Cancer Care Centers
    • Wound Care Centers
    • Others

Company Profiles

  • Alnylam Pharmaceuticals Inc.
    • Company Overview
    • Geographic Footprints
    • Financial Performance
    • Product Portfolio
    • SWOT Analysis
    • R&D Efforts
    • Recent Developments & Strategic Collaborations
      • Product Launch/M&A/Technical Collaboration
  • Amgen Inc.
  • Biogen Inc.
  • CORESTEM Inc.
  • Dendreon Pharmaceuticals LLC.
  • Helixmith Co. Ltd.
  • JCR Pharmaceuticals Co. Ltd.
  • Kolon TissueGene Inc.
  • Novartis AG
  • Pfizer Inc.

Conclusion & Recommendations

  • Insight Code: 5052
  • No. of Pages: 150
  • Format: PDF/PPT/Excel
  • Published: May 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Rohan Patil is a seasoned market research professional with over 5 years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

He began his journey with Precedence Research, where he played a pivotal role in developing high-impact healthcare market reports. Today, Rohan leads research initiatives at Towards Healthcare, while also contributing to Statifacts, where he supports cross-industry analysis and data-driven storytelling.

Rohan’s core strengths lie in trend analysis and emerging technologies, regulatory monitoring and thought leadership through high-quality report writing. He excels at identifying future-ready opportunities and translating complex data into strategic recommendations. His work spans pharmaceuticals, biotechnology, medical devices, and digital health, assessing everything from market potential and competitive positioning to customer needs and regulatory shifts.

A trusted advisor and a relentless innovator, Rohan continues to push the boundaries of traditional market research, merging scientific rigor with commercial insight to stay ahead in a fast-evolving healthcare landscape.

Talk to us
FAQ's

Cell and gene therapy has shown promise in the treatment of various diseases, including genetic disorders, cancer, cardiovascular diseases, neurodegenerative disorders, and autoimmune diseases. Specific examples include inherited genetic disorders like cystic fibrosis and sickle cell anemia, certain types of leukemia and lymphoma, and neurodegenerative conditions like Parkinsos and Alzheimers diseases.

Like any medical intervention, cell and gene therapy carries certain risks and potential side effects. These can include immune reactions, inflammation, infection, or the possibility of unexpected outcomes. However, rigorous safety assessments and monitoring protocols are in place to minimize these risks. Clinical trials and regulatory approvals ensure that therapies are thoroughly evaluated for their safety and efficacy before being made available to patients.

Cell and gene therapy offers several benefits. It has the potential to provide targeted and personalized treatments, especially for genetic disorders and certain types of cancer. These therapies can address unmet medical needs, improve patient outcomes, and potentially offer long-term or curative solutions. They also have the advantage of being less invasive than traditional treatments, reducing the need for prolonged hospital stays and minimizing side effects.

American Society of Cell + Gene Therapy, U.S. Food & Drug Administration, National Library of Medicine, and American Cancer Society
Any Questions